BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 32747558)

  • 1. Multidimensional study of the heterogeneity of leukemia cells in t(8;21) acute myelogenous leukemia identifies the subtype with poor outcome.
    Jiang L; Li XP; Dai YT; Chen B; Weng XQ; Xiong SM; Zhang M; Huang JY; Chen Z; Chen SJ
    Proc Natl Acad Sci U S A; 2020 Aug; 117(33):20117-20126. PubMed ID: 32747558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of CD34
    Li X; Dai Y; Chen B; Huang J; Chen S; Jiang L
    Front Med; 2021 Aug; 15(4):608-620. PubMed ID: 33754282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD117/CD34 expression in leukemic blasts.
    Wells SJ; Bray RA; Stempora LL; Farhi DC
    Am J Clin Pathol; 1996 Aug; 106(2):192-5. PubMed ID: 8712172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of CD34
    Li XP; Zhang WN; Mao JY; Zhao BT; Jiang L; Gao Y
    J Transl Med; 2022 Aug; 20(1):359. PubMed ID: 35962395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
    Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
    BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
    Liu YR; Wang YZ; Chen SS; Chang Y; Fu JY; Li LD; Wang H; Yu H; Jiang B; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117.
    Haase D; Feuring-Buske M; Schäfer C; Schoch C; Troff C; Gahn B; Hiddemann W; Wörmann B
    Leukemia; 1997 May; 11(5):674-9. PubMed ID: 9180291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
    Zhao F; Chen Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid Neoplasms with Elevated Plasmacytoid Dendritic Cell Differentiation Reflect the Maturation Process of Dendritic Cells.
    Huang Y; Wang Y; Chang Y; Yuan X; Hao L; Shi H; Lai Y; Huang X; Liu Y
    Cytometry A; 2020 Jan; 97(1):61-69. PubMed ID: 31876105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD45
    Heo SK; Noh EK; Ju LJ; Sung JY; Jeong YK; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
    BMC Cancer; 2020 Apr; 20(1):285. PubMed ID: 32252668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype.
    Cascavilla N; Musto P; D'Arena G; Melillo L; Carella AM; Petrilli MP; Sanpaolo G; Carotenuto M
    Haematologica; 1998 May; 83(5):392-7. PubMed ID: 9658721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of CD90, CD96, CD117, and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia.
    Chávez-González A; Dorantes-Acosta E; Moreno-Lorenzana D; Alvarado-Moreno A; Arriaga-Pizano L; Mayani H
    Arch Med Res; 2014 May; 45(4):343-50. PubMed ID: 24751333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-kit receptor tyrosine kinase (CD117) expression and its positive predictive value for the diagnosis of Thai adult acute myeloid leukemia.
    Auewarakul CU; Lauhakirti D; Promsuwicha O; Munkhetvit C
    Ann Hematol; 2006 Feb; 85(2):108-12. PubMed ID: 16320053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD34 expression in native human acute myelogenous leukemia blasts: differences in CD34 membrane molecule expression are associated with different gene expression profiles.
    Oyan AM; Bø TH; Jonassen I; Ulvestad E; Gjertsen BT; Kalland KH; Bruserud O
    Cytometry B Clin Cytom; 2005 Mar; 64(1):18-27. PubMed ID: 15668952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): reduced immunogenicity and high frequency of CD34+/CD38- leukemic progenitors.
    Costello R; Mallet F; Chambost H; Sainty D; Arnoulet C; Gastaut JA; Olive D
    Leukemia; 1999 Oct; 13(10):1513-8. PubMed ID: 10516751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential responses of CD34-positive acute myelogenous leukemic blasts to the costimulating effects of stem cell factor with GM-CSF and/or IL-3.
    Min YH; Lee ST; Lee BK; Chong SY; Lee S; Hahn JS; Ko YW
    Yonsei Med J; 1995 Mar; 36(1):26-36. PubMed ID: 7537932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
    Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
    Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome.
    Casasnovas RO; Slimane FK; Garand R; Faure GC; Campos L; Deneys V; Bernier M; Falkenrodt A; Lecalvez G; Maynadié M; Béné MC
    Leukemia; 2003 Mar; 17(3):515-27. PubMed ID: 12646939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia.
    Vergez F; Largeaud L; Bertoli S; Nicolau ML; Rieu JB; Vergnolle I; Saland E; Sarry A; Tavitian S; Huguet F; Picard M; Vial JP; Lechevalier N; Bidet A; Dumas PY; Pigneux A; Luquet I; Mansat-De Mas V; Delabesse E; Carroll M; Danet-Desnoyers G; Sarry JE; Récher C
    Blood Cancer J; 2022 Aug; 12(8):117. PubMed ID: 35973983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance.
    Schwartz S; Heinecke A; Zimmermann M; Creutzig U; Schoch C; Harbott J; Fonatsch C; Löffler H; Büchner T; Ludwig WD; Thiel E
    Leuk Lymphoma; 1999 Jun; 34(1-2):85-94. PubMed ID: 10350335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.